vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and SMITH & WESSON BRANDS, INC. (SWBI). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $124.7M, roughly 1.6× SMITH & WESSON BRANDS, INC.). SMITH & WESSON BRANDS, INC. runs the higher net margin — 1.5% vs -14.6%, a 16.1% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -3.9%). SMITH & WESSON BRANDS, INC. produced more free cash flow last quarter ($16.3M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -4.8%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
AXSM vs SWBI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $124.7M |
| Net Profit | $-28.6M | $1.9M |
| Gross Margin | — | 24.3% |
| Operating Margin | -13.8% | 3.3% |
| Net Margin | -14.6% | 1.5% |
| Revenue YoY | 65.0% | -3.9% |
| Net Profit YoY | 61.9% | -53.6% |
| EPS (diluted) | $-0.55 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $124.7M | ||
| Q3 25 | $171.0M | $85.1M | ||
| Q2 25 | $150.0M | $140.8M | ||
| Q1 25 | $121.5M | $115.9M | ||
| Q4 24 | $118.8M | $129.7M | ||
| Q3 24 | $104.8M | $88.3M | ||
| Q2 24 | $87.2M | $159.1M | ||
| Q1 24 | $75.0M | $137.5M |
| Q4 25 | $-28.6M | $1.9M | ||
| Q3 25 | $-47.2M | $-3.4M | ||
| Q2 25 | $-48.0M | $8.6M | ||
| Q1 25 | $-59.4M | $2.1M | ||
| Q4 24 | $-74.9M | $4.5M | ||
| Q3 24 | $-64.6M | $-1.9M | ||
| Q2 24 | $-79.3M | $27.9M | ||
| Q1 24 | $-68.4M | $7.9M |
| Q4 25 | — | 24.3% | ||
| Q3 25 | — | 25.9% | ||
| Q2 25 | — | 28.8% | ||
| Q1 25 | — | 24.1% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | — | 35.5% | ||
| Q1 24 | — | 28.7% |
| Q4 25 | -13.8% | 3.3% | ||
| Q3 25 | -27.0% | -3.5% | ||
| Q2 25 | -24.5% | 9.3% | ||
| Q1 25 | -46.9% | 4.1% | ||
| Q4 24 | -61.1% | 5.8% | ||
| Q3 24 | -59.8% | -1.7% | ||
| Q2 24 | -89.5% | 17.4% | ||
| Q1 24 | -89.7% | 8.2% |
| Q4 25 | -14.6% | 1.5% | ||
| Q3 25 | -27.6% | -4.0% | ||
| Q2 25 | -32.0% | 6.1% | ||
| Q1 25 | -48.9% | 1.8% | ||
| Q4 24 | -63.1% | 3.5% | ||
| Q3 24 | -61.7% | -2.1% | ||
| Q2 24 | -91.0% | 17.5% | ||
| Q1 24 | -91.1% | 5.7% |
| Q4 25 | $-0.55 | $0.04 | ||
| Q3 25 | $-0.94 | $-0.08 | ||
| Q2 25 | $-0.97 | $0.19 | ||
| Q1 25 | $-1.22 | $0.05 | ||
| Q4 24 | $-1.54 | $0.10 | ||
| Q3 24 | $-1.34 | $-0.04 | ||
| Q2 24 | $-1.67 | $0.60 | ||
| Q1 24 | $-1.44 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $22.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $363.2M |
| Total Assets | $689.8M | $548.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $22.4M | ||
| Q3 25 | $325.3M | $18.0M | ||
| Q2 25 | $303.0M | $25.2M | ||
| Q1 25 | $300.9M | $26.7M | ||
| Q4 24 | $315.4M | $39.1M | ||
| Q3 24 | $327.3M | $35.5M | ||
| Q2 24 | $315.7M | $60.8M | ||
| Q1 24 | $331.4M | $47.4M |
| Q4 25 | $88.3M | $363.2M | ||
| Q3 25 | $73.7M | $364.4M | ||
| Q2 25 | $73.1M | $372.5M | ||
| Q1 25 | $53.2M | $366.9M | ||
| Q4 24 | $57.0M | $371.5M | ||
| Q3 24 | $92.9M | $380.0M | ||
| Q2 24 | $102.9M | $399.9M | ||
| Q1 24 | $144.0M | $376.4M |
| Q4 25 | $689.8M | $548.6M | ||
| Q3 25 | $669.3M | $554.6M | ||
| Q2 25 | $639.8M | $559.6M | ||
| Q1 25 | $596.7M | $578.9M | ||
| Q4 24 | $568.5M | $587.4M | ||
| Q3 24 | $561.5M | $571.3M | ||
| Q2 24 | $548.2M | $577.4M | ||
| Q1 24 | $545.7M | $570.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $27.3M |
| Free Cash FlowOCF − Capex | $-18.7M | $16.3M |
| FCF MarginFCF / Revenue | -9.6% | 13.1% |
| Capex IntensityCapex / Revenue | 0.0% | 8.8% |
| Cash ConversionOCF / Net Profit | — | 14.22× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $21.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $27.3M | ||
| Q3 25 | $1.0M | $-8.1M | ||
| Q2 25 | $-32.4M | $40.8M | ||
| Q1 25 | $-43.4M | $-9.8M | ||
| Q4 24 | $-26.2M | $-7.4M | ||
| Q3 24 | $-18.6M | $-30.8M | ||
| Q2 24 | $-30.1M | $43.7M | ||
| Q1 24 | $-53.5M | $25.2M |
| Q4 25 | $-18.7M | $16.3M | ||
| Q3 25 | $988.0K | $-12.4M | ||
| Q2 25 | $-32.4M | $33.5M | ||
| Q1 25 | $-43.7M | $-16.1M | ||
| Q4 24 | $-26.2M | $-10.7M | ||
| Q3 24 | $-18.7M | $-35.5M | ||
| Q2 24 | $-30.2M | $38.2M | ||
| Q1 24 | $-53.6M | $7.0M |
| Q4 25 | -9.6% | 13.1% | ||
| Q3 25 | 0.6% | -14.6% | ||
| Q2 25 | -21.6% | 23.8% | ||
| Q1 25 | -36.0% | -13.9% | ||
| Q4 24 | -22.1% | -8.3% | ||
| Q3 24 | -17.9% | -40.2% | ||
| Q2 24 | -34.6% | 24.0% | ||
| Q1 24 | -71.4% | 5.1% |
| Q4 25 | 0.0% | 8.8% | ||
| Q3 25 | 0.0% | 5.0% | ||
| Q2 25 | 0.0% | 5.2% | ||
| Q1 25 | 0.3% | 5.4% | ||
| Q4 24 | 0.0% | 2.5% | ||
| Q3 24 | 0.1% | 5.3% | ||
| Q2 24 | 0.1% | 3.5% | ||
| Q1 24 | 0.1% | 13.2% |
| Q4 25 | — | 14.22× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 4.73× | ||
| Q1 25 | — | -4.68× | ||
| Q4 24 | — | -1.63× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.57× | ||
| Q1 24 | — | 3.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
